Daily BriefsJapan

Daily Brief Japan: Fuji Soft Inc, Open House, Shinko Electric Industries, Saizeriya, Sumitomo Pharma and more

In today’s briefing:

  • Fuji Soft (9749) – Much Better Governance Process But The Stock Has Run Too Far
  • Japan – Increasing Shorts on Some Interesting* Stocks; Positioning Appears Light
  • Merger Arb Mondays (15 Jan) – Shinko Electric, Benefit One, T&K Toka, Taisho, IJTT, IRC, Weiqiao
  • Saizeriya (7581 JP):  Asia Business Slightly Beat While Japan Operating Profit Missed
  • Sumitomo Pharma (4506 JP): FY24 Guidance Seems to Be Aggressive; Downtrend Will Likely To Continue


Fuji Soft (9749) – Much Better Governance Process But The Stock Has Run Too Far

By Travis Lundy

  • After 3D Investment Partners bought a large slug of Fuji Soft Inc (9749 JP) in early 2022, the company started a review of governance and capital allocation. 
  • The company updated investors in August, and bought in 4 listed subs in November-December 2023. The August update suggested a Q1 2024 decision on use/ownership of real estate.
  • The Final Report is due in a month. In the meantime, the stock rallied Friday off a news article suggesting the Board was reviewing take-private proposals. Yes, but…

Japan – Increasing Shorts on Some Interesting* Stocks; Positioning Appears Light

By Brian Freitas

  • Some stocks have continued to underperform the Nikkei 225 (NKY INDEX) and their peers and could be deleted from global passive portfolios next month.
  • Stocks that were expected to be deleted (but could now be safe) have outperformed the Nikkei 225 (NKY INDEX) over the last couple of weeks.
  • There has been two-way flow in a lot of stocks with market participants increasing and covering short positions as the stock prices have moved around.


Saizeriya (7581 JP):  Asia Business Slightly Beat While Japan Operating Profit Missed

By Steve Zhou, CFA

  • Saizeriya (7581 JP) reported FY1Q24 results (September to November) last week.  Sales grew 22% yoy, and was 2% higher than company guidance.  Operating profit grew 104%.
  • Operating profit for the Asia business, the key growth driver of the company, was Y3.3bn, up 56% yoy and above management guidance. 
  • Overall thesis remains intact, as the Asia business performed slightly better than expectations. 

Sumitomo Pharma (4506 JP): FY24 Guidance Seems to Be Aggressive; Downtrend Will Likely To Continue

By Tina Banerjee

  • Sumitomo Pharma (4506 JP) still expects FY24 revenue of ¥362 billion (down 35% YoY). This implies H2FY24 revenue of ¥209.4 billion, up 37% compared with H1FY24.
  • To achieve this target, North America needs to perform strongly. H1FY24 revenue from North America has shown a progress rate of just 35% against full-year FY24 revenue guidance.
  • With the absence of any strong catalyst, we expect recent rally in Sumitomo shares fueled by encouraging clinical trial result and new drug approval in China, will be short-lived.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars